Abstract:
Eyebrow hypotrichosis is a condition that affects a persons appearance and self-confidence. Topical treatments such as minoxidil and bimatoprost have gained increasing interest for promoting eyebrow hair density and regrowth. This study aimed to compare the efficacy and safety of 5% minoxidil versus 0.03% bimatoprost in the treatment of eyebrow hypotrichosis. A randomized, double-blind, split-side controlled trial was conducted in eligible volunteers who consented to participate. A total of 21 subjects completed the 12-week study period.
The results showed that 38.1% of participants in the 5% minoxidil group achieved a Global Clinical Improvement score of ≥ +2 at week 12, compared to 19.0% in the bimatoprost group (p = 0.05). In addition, hair shaft thickness measured by video dermoscopy significantly increased in the minoxidil group (Δmean = 17.9 ± 8.4 µ) compared to the bimatoprost group (Δmean = 13.8 ± 7.7 µ) (p = 0.001).
Regarding patient satisfaction, both groups reported comparable mean scores (p = 0.317). However, two participants (9.5%) in the minoxidil group experienced adverse skin reactions, including irritation and erythema, while no adverse effects were reported in the bimatoprost group.
In conclusion, 5% minoxidil demonstrated greater potential for improving eyebrow thickness and clinical response within 12 weeks, though safety considerations should be addressed, especially in individuals with sensitive skin. This study provides clinically relevant insights for selecting appropriate and safe treatment options for eyebrow hypotrichosis.